Ultragenyx Pharmaceutical Inc. (RARE)
NASDAQ: RARE · Real-Time Price · USD
29.28
-0.94 (-3.11%)
At close: Jul 17, 2026, 4:00 PM EDT
29.35
+0.07 (0.24%)
After-hours: Jul 17, 2026, 5:08 PM EDT
Ultragenyx Pharmaceutical Revenue
Ultragenyx Pharmaceutical had revenue of $136.00M in the quarter ending March 31, 2026, a decrease of -2.16%. This brings the company's revenue in the last twelve months to $669.71M, up 13.48% year-over-year. In the year 2025, Ultragenyx Pharmaceutical had annual revenue of $673.00M with 20.18% growth.
Revenue (ttm)
$669.71M
Revenue Growth
+13.48%
P/S Ratio
4.29
Revenue / Employee
$488,694
Employees
1,371
Market Cap
2.87B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 673.00M | 113.00M | 20.18% |
| Dec 31, 2024 | 560.00M | 126.00M | 29.03% |
| Dec 31, 2023 | 434.00M | 70.67M | 19.45% |
| Dec 31, 2022 | 363.33M | 11.92M | 3.39% |
| Dec 31, 2021 | 351.41M | 80.38M | 29.66% |
| Dec 31, 2020 | 271.03M | 167.32M | 161.32% |
| Dec 31, 2019 | 103.71M | 52.22M | 101.41% |
| Dec 31, 2018 | 51.50M | 48.88M | 1,871.48% |
| Dec 31, 2017 | 2.61M | 2.48M | 1,863.91% |
| Dec 31, 2016 | 133.00K | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
| Dec 31, 2011 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Arcus Biosciences | 236.00M |
| IDEAYA Biosciences | 225.27M |
| Beam Therapeutics | 164.01M |
| uniQure | 18.09M |
| AtaiBeckley | 3.49M |
| Celldex Therapeutics | 865.00K |
RARE News
- 2 days ago - Johnson Fistel, PLLP Investigates Claims on Behalf of Long-Term Shareholders of Ultragenyx Pharmaceutical Inc. (RARE) - GlobeNewsWire
- 4 days ago - Ultragenyx price target raised to $30 from $26 at Wedbush - TheFly
- 9 days ago - Ultragenyx Releases 2025 Impact Report Emphasizing Commitment to Rare Disease Patients, Innovation, and Global Impact - GlobeNewsWire
- 10 days ago - Ultragenyx price target raised to $40 from $35 at RBC Capital - TheFly
- 4 weeks ago - Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 5 weeks ago - Ultragenyx Pharmaceutical Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 6 weeks ago - Ultragenyx to Participate at Goldman Sachs 47th Annual Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Ultragenyx price target raised to $96 from $84 at Cantor Fitzgerald - TheFly